Export financials
Retractable Technologies (RVP)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.

Retractable Technologies Income Statement 2025-2008 | RVP
Brief overview of profit and loss at Retractable Technologies
This overview is based on financial performance over the past five years. Revenue reported by Retractable Technologies was $81.9 million at the beginning of the period and $38.3 million at the end. The cumulative result was −53.3%, corresponding to roughly −14.1% per year. Sales followed a declining trajectory over the five years.
The gross result shifted from $37 million to $47 thousand, or −99.9%. The cost base moved against the top-line trend and weighed on the gross result. The gross margin was 45.2% at the start and 0.1% at the end. The contraction points to pressure from direct costs or weaker pricing power.
Over the period, EBITDA shifted from $24.9 million to −$13.4 million, a change of −153.8%. EBITDA underperformed the top-line trend. At the operating-margin level, the figure shifted from 30.4% to −35%. The business retained less EBITDA from each unit of revenue.
Across the five years, the net result shifted from 24.2 million dollars to −12.6 million dollars. The move from profit to loss indicates a material deterioration in final efficiency.
Market capitalization changed from $534 million to $20.1 million (−96.2%). Market value lagged the financial performance.
Summary assessment
The financial trajectory is weak and requires a cautious interpretation. The weaker side of the profile includes pressure on operating profitability, a lower gross margin and declining net profitability. Investors should continue to monitor margins, costs, and earnings quality.
Annual Income Statement Retractable Technologies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
20.1 M | 21 M | 35.9 M | 56.9 M | 185 M | 534 M | 52.6 M | 22.5 M | 24 M | 33.5 M | 81 M | 115 M | 92.1 M | 25.2 M | 39.2 M | 40.6 M | 20.9 M | - |
Shares |
29.9 M | 29.9 M | 29.9 M | 32.9 M | 33.9 M | 33.2 M | 32.7 M | 32.7 M | 32 M | 29.4 M | 27.8 M | 27.4 M | 27 M | 26.2 M | 24.2 M | 23.9 M | 23.8 M | - |
Historical Prices |
0.67 | 0.7 | 1.2 | 1.73 | 5.46 | 16.1 | 1.6 | 0.7 | 0.73 | 1.14 | 2.91 | 4.21 | 3.55 | 0.95 | 1.65 | 1.7 | 0.88 | 1.32 |
Net Income |
-12.6 M | -11.9 M | -7.01 M | 5.08 M | 56.1 M | 24.2 M | 3.15 M | -1.34 M | -3.74 M | -3.69 M | 4.31 M | -2.35 M | -6.21 M | -4.13 M | 1.42 M | 2.4 M | -9.42 M | - |
Revenue |
38.3 M | 33 M | 43.6 M | 94.8 M | 188 M | 81.9 M | 41.8 M | 33.3 M | 34.5 M | 29.8 M | 29.6 M | 34.5 M | 30.8 M | 33.6 M | 32.1 M | - | - | - |
Cost of Revenue |
38.2 M | 34.1 M | 34.5 M | 66.6 M | 93 M | 44.9 M | 27.7 M | 23.1 M | 24.5 M | 19.5 M | 19 M | 22.5 M | 20.5 M | 22.5 M | 21.2 M | 23.7 M | 25.5 M | - |
Gross Profit |
47 K | -1.03 M | 9.11 M | 28.3 M | 95.4 M | 37 M | 14.1 M | 10.2 M | 9.97 M | 10.3 M | 10.6 M | 12 M | 10.3 M | 11.2 M | 10.9 M | 12.5 M | 13.5 M | - |
Operating Income |
-21.2 M | -21.1 M | -11.5 M | -853 K | 72.6 M | 24.1 M | 2.97 M | -1.33 M | -3.78 M | -3.51 M | -3.21 M | -2.16 M | -5.93 M | -3.94 M | -4.09 M | -6.66 M | -13.3 M | - |
Interest Expense |
- | - | 152 K | 171 K | 227 K | 260 K | 167 K | 177 K | 211 K | 213 K | 220 K | 223 K | 231 K | 231 K | 240 K | 303 K | 21.9 K | - |
EBITDA |
-13.4 M | -13.5 M | -3.96 M | 3.75 M | 73.9 M | 24.9 M | 3.82 M | -694 K | -2.94 M | -2.18 M | -2.35 M | -1.08 M | -4.65 M | -2.6 M | -2.78 M | -5.15 M | -11.9 M | - |
Operating Expenses |
21.2 M | 20.1 M | 20.6 M | 29.1 M | 22.8 M | 12.9 M | 11.2 M | 11.8 M | 13.8 M | 13.4 M | 13.8 M | 14.2 M | 16.2 M | 15.1 M | 15 M | 19.2 M | 26.8 M | - |
General and Administrative Expenses |
12.8 M | 13.6 M | 14.3 M | 24 M | 17.4 M | 8.3 M | 6.43 M | 6.78 M | 8.35 M | 8.8 M | 9.33 M | 9.6 M | 11 M | 10 M | 10.7 M | 14.3 M | 18.8 M | - |
All numbers in USD currency
Quarterly Income Statement Retractable Technologies
| 2026-Q1 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 29.9 M | 32.9 M | 32.9 M | 33.3 M | 33.5 M | 33.9 M | 34 M | 34 M | 34 M | 33.4 M | 32.8 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 32.7 M | 32.2 M | 31.7 M | 31.3 M | 29.7 M | 29.6 M | 29.5 M | 28.6 M | 28.6 M | 27.9 M | 27.7 M | 27.7 M | 27.6 M | 27.4 M | 27.3 M | 27.3 M | 27.2 M | 26.7 M | 27 M | 27.2 M | 27.3 M | 27 M | 25.3 M | 25.3 M | 25.3 M | 24 M | 24 M | 24 M |
Net Income |
-4.23 M | 371 K | -87.5 K | -10.5 M | - | -1.92 M | -14.2 M | 429 K | - | -4.06 M | -3.87 M | 991 K | - | 5.39 M | -3.64 M | 7.62 M | - | 6.52 M | 10.7 M | 18 M | - | 8.63 M | 3.77 M | 323 K | 1.86 M | 1.02 M | 392 K | -129 K | -150 K | -63 K | -948 K | -179 K | - | -66.6 K | -1.35 M | -1.19 M | - | -125 K | -657 K | -939 K | - | -255 K | 6.44 M | -944 K | - | 371 K | -1.39 M | -2.04 M | - | -940 K | -2.44 M | -1.41 M | - | -273 K | -605 K | -714 K | - | 1.83 M | 847 K | 1.72 M |
Revenue |
7.18 M | 10.1 M | 10.4 M | 8.3 M | - | 10.3 M | 6.03 M | 7.6 M | - | 10.3 M | 7.97 M | 11 M | - | 23.1 M | 14.3 M | 44.7 M | - | 36.4 M | 42.5 M | 50.1 M | - | 27.1 M | 11.6 M | 11.2 M | 12.6 M | 11.6 M | 9.6 M | 7.93 M | 8.26 M | 9.86 M | 7.48 M | 7.67 M | - | 10.4 M | 7.65 M | 6.92 M | - | 8.84 M | 7.58 M | 5.92 M | - | 9.48 M | 6.72 M | 6.18 M | - | 10.9 M | 6.88 M | 6.04 M | - | 9.16 M | 6.91 M | 7.17 M | - | 9.44 M | 8.73 M | 7.43 M | - | 8.27 M | 7.98 M | 9.75 M |
Cost of Revenue |
8.02 M | 8.4 M | 10.6 M | 8.3 M | - | 10.4 M | 6.45 M | 5.7 M | - | 6.01 M | 7.59 M | 8.13 M | - | 18.3 M | 10.7 M | 29.2 M | - | 23 M | 22.9 M | 22.1 M | - | 13.3 M | 7.9 M | 7.67 M | 7.68 M | 7.87 M | 6.66 M | 5.44 M | 5.77 M | 7.07 M | 5.41 M | 4.81 M | - | 7.15 M | 5.44 M | 4.6 M | - | 5.58 M | 4.96 M | 3.73 M | - | 6.26 M | 4.11 M | 3.78 M | - | 7.03 M | 4.7 M | 4.32 M | - | 5.84 M | 5.17 M | 4.4 M | - | 6.09 M | 5.4 M | 4.59 M | - | 4.88 M | 4.84 M | 6.46 M |
Gross Profit |
-838 K | 1.69 M | -107 K | -1.91 K | - | -14.8 K | -420 K | 1.9 M | - | 4.32 M | 377 K | 2.87 M | - | 4.74 M | 3.65 M | 15.6 M | - | 13.4 M | 19.6 M | 28 M | - | 13.8 M | 3.67 M | 3.53 M | 4.95 M | 3.77 M | 2.93 M | 2.49 M | 2.5 M | 2.8 M | 2.07 M | 2.86 M | - | 3.26 M | 2.21 M | 2.32 M | - | 3.26 M | 2.62 M | 2.19 M | - | 3.22 M | 2.6 M | 2.4 M | - | 3.85 M | 2.18 M | 1.72 M | - | 3.32 M | 1.74 M | 2.78 M | - | 3.35 M | 3.33 M | 2.84 M | - | 3.39 M | 3.14 M | 3.29 M |
Operating Income |
-6.17 M | -3.65 M | -5.13 M | -4.68 M | - | -5.14 M | -5.76 M | -2.99 M | - | -936 K | -5.03 M | -2.74 M | - | -691 K | -2.06 M | 9.73 M | - | 7.97 M | 12.7 M | 23.4 M | - | 10.3 M | 960 K | 481 K | - | 978 K | 329 K | -175 K | - | -60.2 K | -939 K | -157 K | - | -32.9 K | -1.31 M | -1.15 M | - | -81.4 K | -606 K | -894 K | - | -199 K | -1.24 M | -895 K | - | 421 K | -1.34 M | -1.99 M | - | -825 K | -2.39 M | -1.37 M | - | -211 K | -532 K | -645 K | - | -26.4 K | -988 K | -99.9 K |
Interest Expense |
- | - | - | - | - | - | - | 33.5 K | - | 36.1 K | 37.5 K | 43.6 K | - | 40.3 K | 38.4 K | 47.1 K | - | 52.9 K | 54.7 K | 65.1 K | - | 36.1 K | 36 K | 33.8 K | 36 K | 40.7 K | 43.5 K | 45.9 K | 41 K | 42 K | 44 K | 50 K | - | 53 K | 58 K | 48.1 K | - | 52 K | 56.7 K | 49.6 K | - | 58.3 K | 53.1 K | 53.8 K | - | 55.2 K | 56 K | 57.2 K | - | 59.5 K | 60.6 K | 52.1 K | - | 69 K | 70.3 K | 72.1 K | - | 62.5 K | 65.5 K | 56.9 K |
EBITDA |
-4.26 M | - | - | -2.79 M | - | - | - | -1.1 M | - | - | - | -802 K | - | 2.29 M | -284 K | 10.4 M | - | 8.67 M | 13.1 M | 23.6 M | - | 11 M | 1.38 M | 691 K | - | 1.62 M | 756 K | 37 K | - | 609 K | -486 K | 72.8 K | - | 571 K | -900 K | -945 K | - | 591 K | -159 K | -690 K | - | 446 K | -806 K | -669 K | - | 421 K | -1.34 M | -1.66 M | - | 132 K | -1.76 M | -1.05 M | - | 775 K | 134 K | -316 K | - | 961 K | -333 K | 228 K |
Operating Expenses |
5.33 M | 5.34 M | 5.02 M | 4.67 M | - | 5.12 M | 5.34 M | 4.89 M | - | 5.26 M | 5.41 M | 5.61 M | - | 5.43 M | 5.71 M | 5.84 M | - | 5.43 M | 6.97 M | 4.57 M | - | 3.48 M | 2.71 M | 3.05 M | - | 2.79 M | 2.6 M | 2.67 M | - | 2.86 M | 3.01 M | 3.02 M | - | 3.29 M | 3.51 M | 3.48 M | - | 3.34 M | 3.22 M | 3.08 M | - | 3.42 M | 3.84 M | 3.29 M | - | 3.43 M | 3.52 M | 3.71 M | - | 4.14 M | 4.12 M | 4.14 M | - | 3.57 M | 3.86 M | 3.49 M | - | 3.42 M | 4.12 M | 3.39 M |
General and Administrative Expenses |
3.43 M | 3.56 M | 3.2 M | 2.88 M | - | 3.2 M | 3.67 M | 3.31 M | - | 3.74 M | 3.73 M | 4.13 M | - | 4.15 M | 4.44 M | 4.73 M | - | 4.21 M | 5.12 M | 3.49 M | - | 2.19 M | 1.74 M | 1.78 M | - | 1.65 M | 1.51 M | 1.66 M | - | 1.68 M | 1.81 M | 1.71 M | - | 1.91 M | 2.13 M | 2.3 M | - | 2.17 M | 2.09 M | 2.05 M | - | 2.34 M | 2.66 M | 2.32 M | - | 2.38 M | 2.26 M | 2.43 M | - | 2.78 M | 2.85 M | 2.9 M | - | 2.29 M | 2.68 M | 2.4 M | - | 2.31 M | 3.15 M | 2.44 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company Retractable Technologies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
- | - | $ 810 M | ||
|
electroCore
ECOR
|
$ 11.42 | 2.46 % | $ 96.9 K | ||
|
Alcon
ALC
|
$ 65.39 | 0.02 % | $ 32.3 B | ||
|
Glaukos Corporation
GKOS
|
$ 153.49 | 0.19 % | $ 8.78 B | ||
|
Haemonetics Corporation
HAE
|
$ 106.82 | 0.01 % | $ 5.04 B | ||
|
Harvard Bioscience
HBIO
|
$ 8.05 | 1.64 % | $ 357 M | ||
|
InfuSystem Holdings
INFU
|
$ 12.7 | 2.26 % | $ 262 M | ||
|
iRhythm Technologies
IRTC
|
$ 111.75 | 1.1 % | $ 3.58 B | ||
|
Intuitive Surgical
ISRG
|
$ 398.3 | 0.06 % | $ 142 B | ||
|
AngioDynamics
ANGO
|
$ 15.51 | 0.26 % | $ 644 M | ||
|
Repro Med Systems
KRMD
|
$ 3.27 | 2.42 % | $ 151 M | ||
|
LeMaitre Vascular
LMAT
|
$ 80.58 | 0.12 % | $ 1.82 B | ||
|
Microbot Medical
MBOT
|
$ 1.31 | 0.36 % | $ 60 M | ||
|
Merit Medical Systems
MMSI
|
$ 87.07 | 0.1 % | $ 5.15 B | ||
|
Nephros
NEPH
|
$ 4.29 | 2.88 % | $ 45.5 M | ||
|
Envista Holdings Corporation
NVST
|
$ 23.82 | 0.41 % | $ 4 B | ||
|
OraSure Technologies
OSUR
|
$ 3.99 | 8.13 % | $ 293 M | ||
|
Pro-Dex
PDEX
|
$ 71.94 | 0.12 % | $ 232 B | ||
|
Pulse Biosciences
PLSE
|
$ 51.98 | 0.25 % | $ 3.5 B | ||
|
Repligen Corporation
RGEN
|
$ 184.53 | 0.81 % | $ 10.4 M | ||
|
AtriCure
ATRC
|
$ 59.96 | 1.91 % | $ 2.86 B | ||
|
STAAR Surgical Company
STAA
|
$ 19.8 | 1.62 % | $ 981 M | ||
|
STERIS plc
STE
|
$ 209.98 | 0.61 % | $ 20.6 B | ||
|
Stereotaxis
STXS
|
$ 1.32 | 2.94 % | $ 120 M | ||
|
BioLife Solutions
BLFS
|
$ 37.74 | 0.37 % | $ 1.8 B | ||
|
Baxter International
BAX
|
$ 23.49 | 0.17 % | $ 12.1 B | ||
|
Utah Medical Products
UTMD
|
$ 75.01 | 2.93 % | $ 243 M | ||
|
West Pharmaceutical Services
WST
|
$ 375.87 | 1.29 % | $ 27.2 B | ||
|
Becton, Dickinson and Company
BDX
|
$ 182.52 | 0.01 % | $ 52.5 B | ||
|
DENTSPLY SIRONA
XRAY
|
$ 9.78 | 0.05 % | $ 1.95 B | ||
|
The Cooper Companies
COO
|
$ 56.07 | 1.41 % | $ 11.2 B | ||
|
ICU Medical
ICUI
|
$ 163.32 | 1.45 % | $ 4.02 B | ||
|
Milestone Scientific
MLSS
|
$ 0.42 | 4.73 % | $ 34.5 M | ||
|
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | ||
|
Teleflex Incorporated
TFX
|
$ 121.75 | 0.08 % | $ 5.43 B | ||
|
ResMed
RMD
|
$ 222.3 | 0.15 % | $ 32.3 B | ||
|
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | ||
|
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | ||
|
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | ||
|
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | ||
|
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | ||
|
Ekso Bionics Holdings
EKSO
|
- | - | $ 28.6 M | ||
|
Isoray
ISR
|
- | 0.03 % | $ 108 M | ||
|
Masimo Corporation
MASI
|
- | - | $ 9.59 B | ||
|
Predictive Oncology
POAI
|
- | - | $ 31.1 M |